title: Nanotechnology approaches for personalized treatment of multidrug resistant cancers.
abstract: The efficacy of chemotherapy is substantially limited by the resistance of cancer cells to anticancer drugs that fluctuates significantly in different patients. Under identical chemotherapeutic protocols, some patients may receive relatively ineffective doses of anticancer agents while other individuals obtain excessive amounts of drugs that induce severe adverse side effects on healthy tissues. The current review is focused on an individualized selection of drugs and targets to suppress multidrug resistance. Such selection is based on the molecular characteristics of a tumor from an individual patient that can potentially improve the treatment outcome and bring us closer to an era of personalized medicine.
authors.affiliation: Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA. Electronic address: minko@rci.rutgers.edu.
authors.forename: Tamara
authors.initials: T
authors.lastname: Minko
authors.forename: Lorna
authors.initials: L
authors.lastname: Rodriguez-Rodriguez
authors.forename: Vitaly
authors.initials: V
authors.lastname: Pozharov
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004705:Endocytosis / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy; D036103:Nanotechnology / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D057285:Precision Medicine / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents
keywords: ABC; ASO; Antibody; Antisense oligonucleotides; CD44; CPT; Cancer stem cells; DBD; DDS; DOX; Drug delivery system; EPR; IC(50) dose; LHRH; NBD; NLC; PAMAM; Passive and active targeting; Peptides; Pump and nonpump resistance; SNP; TMD; TPADDS; a dose that kills 50% of cells; adenosine triphosphate (ATP)-binding cassette; antisense oligonucleotides; camptothecin; doxorubicin; drug delivery system; drug-binding domain; enhanced permeability and retention effect; luteinizing hormone-release hormone; nanostructured lipid carriers; nucleotide-binding domain; poly(amido amine); siRNA; single-nucleotide polymorphism; small interfering RNA; targeted proapoptotic drug delivery system; transmembrane domain